News Focus
News Focus
Followers 2422
Posts 92347
Boards Moderated 1
Alias Born 09/12/2003

Re: xp2k2k3 post# 336

Tuesday, 07/21/2009 4:02:52 AM

Tuesday, July 21, 2009 4:02:52 AM

Post# of 1434
Do you know how to read? It did not come from some small articles on the internet.This news is straight from Aradigm PR.

Aradigm is entitled to a $4 million milestone payment upon first commercial sale, and royalty payments upon any sales of products in the U.S. and other countries, including the European Union, which may be developed and sold using the DosePro technology.

http://finance.yahoo.com/news/Zogenix-Obtains-Approval-in-bw-88503993.html?x=0&.v=1

Form 10-Q
In August 2006, we sold all of our assets related to the Intraject needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to Zogenix, Inc., a private company. Zogenix is responsible for further development and commercialization efforts of Intraject (now rebranded under the name DosePro tm ). We received a $4.0 million initial payment from Zogenix, and we will be entitled to a milestone payment upon initial commercialization, and royalty payments upon any commercialization of products in the U.S. and other countries, including the European Union, that may be developed and sold using the DosePro technology

"On the 10-Q They state very clearly that they received a 4 million for the sale of asset but did not provide any number base on entitled to a milestone payment upon first commercial sale. News on Thursday said Aradigm is entitled to a $4 million milestone payment upon first commercial sale.



Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today